Zynerba Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $86,000 | $0 |
| Operating income | −$35.3M | −$36.8M | −$52.1M | −$34.3M | −$40.4M | −$32.8M |
| Net income | −$35.0M | −$37.3M | −$51.3M | −$32.9M | −$39.9M | −$32.0M |
| Total assets | $55.5M | $81.2M | $74.1M | $87.8M | $67.3M | $69.1M |
| Total liabilities | $9.3M | $10.3M | $13.9M | $12.2M | $9.7M | $8.1M |
| Equity | $46.2M | $70.9M | $60.1M | $75.6M | $57.6M | $60.9M |
| EPS (diluted) | $-0.82 | $-0.95 | $-1.90 | $-1.50 | — | — |
| Shares out. | 42.4M | 41.3M | 23.6M | 21.1M | 13.6M | 13.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −75.8%
- Return on assets
- −63.1%
- Return on capital (ROCE)
- −76.1%
- Liabilities / assets
- 16.7%
- Debt / equity
- 0.20×
- Book value / share
- $1.09
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -9.77distress
- Accruals / assets
- −21.6%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jones Kenneth TOfficer — See Remarks | Oct 10, 2023 | U | 40,520 | — |
| Stephenson PamelaDirector | Oct 10, 2023 | U | 27,954 | — |
| Fickenscher James EOfficer — Chief Financial Officer | Oct 10, 2023 | U | 123,087 | — |
| Sebree Terri BOfficer — President | Oct 10, 2023 | U | 341,241 | — |
| Federici William JDirector | Oct 10, 2023 | U | 27,954 | — |
| Rosenberger BrianOfficer — VP, Commercial & Business Dev. | Oct 10, 2023 | U | 69,559 | — |
| Cooper Warren DDirector | Oct 10, 2023 | U | 27,954 | — |
| Parker Albert POfficer — Chief Legal Officer | Oct 10, 2023 | U | 33,685 | — |
| Butler John P.Director | Oct 10, 2023 | U | 32,941 | — |
| Moch Kenneth IDirector | Oct 10, 2023 | U | 27,954 | — |
| Anido ArmandoOfficer — Chairman & Chief Exec. Officer | Oct 10, 2023 | U | 566,722 | — |
| Kisner Daniel LDirector | Oct 10, 2023 | U | 27,954 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 11, 2023
- Shareholder voteAug 29, 2023
- Entered a material agreement · Director / officer change · Regulation FD disclosureAug 14, 2023
- Shareholder voteJun 14, 2023
- Results of operations · Other material eventMay 15, 2023
- Delisting / listing-standard noticeMay 4, 2023
- Results of operations · Other material eventMar 28, 2023
- Regulation FD disclosureMar 13, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.